Biocon Biologics Signs an Agreement with CHAI to Expand Access to its Oncology Biosimilars in 30 Countries

 Biocon Biologics Signs an Agreement with CHAI to Expand Access to its Oncology Biosimilars in 30 Countries

Biocon Biologics Signs an Agreement with CHAI to Expand Access to its Oncology Biosimilars in 30 Countries

Shots:

  • Biocon and Clinton Health Access Initiative collaborate to expand the offering of oncology biosimilars in over 30 countries including Africa and Asia as a part of the Cancer Access Partnership (CAP)
  • The collaboration strengthens Biocon’s mission to address unmet needs of patients in Asia and Africa for advanced cancer therapies via cost effective biosimilars. The collaboration follows the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs
  • Biocon will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Logo.wine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post